BioSpace News Archive

Nutriband Inc., reported Q1 revenues of $408,532 emphasizing its focus on expanding the company’s Kinesiology Tape manufacturing services through its Pocono Pharma subsidiary.

Cyclacel Pharmaceuticals, Inc. today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data from the CYC065-101 study of fadraciclib as oral monotherapy was presented at a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago, IL.

Johnson & Johnson today announced longer-term data from the pivotal Phase 1/2 MajesTEC-1 study of TECVAYLI® (teclistamab-cqyv) showing deep and durable responses in patients with relapsed or refractory multiple myeloma (RRMM) who are triple-class exposed (TCE)a and who previously received three or more prior lines of therapy, including in patients who switched to less frequent dosing (Abstract #7540).

72nd ASMS Conference on Mass Spectrometry and Allied Topics – Waters Corporation unveiled the Xevo™ MRT, its highest-performing benchtop mass spectrometer, setting new standards for delivering high resolution and speed, critical for large population and epidemiology-type studies.

Stryker announced the signing of a definitive agreement to acquire all of the issued and outstanding shares of Artelon, a privately held company specializing in innovative soft tissue fixation products for foot and ankle and sports medicine procedures.

Aatru Medical, LLC announced that it was awarded 1st Place in Oral Abstracts at the 2024 Spring symposium hosted by the Society for Advanced Wound Care (SAWC).

Fulgent Pharma today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, was presented at the American Society for Clinical Oncology (ASCO) Annual Meeting on June 2, 2024 in Chicago, Illinois.

Glyscend Therapeutics today announced the initiation of a Phase 2 clinical trial of its lead candidate, GLY-200, as a novel oral treatment for obesity.

Ecolab today announced that its Purolite resin business, together with Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of Purolite’s DurA Cycle, a protein A chromatography resin for large-scale purification processes.

Moderna, Inc. (NASDAQ:MRNA) and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from a planned analysis from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study.